What is NewAmsterdam Pharma Company's market cap?

NewAmsterdam Pharma Company (NAMS) has a market capitalization of $3.5B and trades on NASDAQ.

What is NewAmsterdam Pharma Company's revenue and profitability?

NewAmsterdam Pharma Company generated $22.6M in trailing twelve-month revenue with a net loss of $212.7M, representing a net margin of -942.8%, with free cash flow of -$142.2M. These figures are based on the Q1 2026 filing.

Who are NewAmsterdam Pharma Company's competitors?

NewAmsterdam Pharma Company's key competitors include Amgen, Regeneron Pharmaceuticals, Merck & Co., and others. These companies compete in similar markets and product categories.

Who does NewAmsterdam Pharma Company partner with?

NewAmsterdam Pharma Company's notable partners include Menarini, Amgen, Mitsubishi Tanabe Pharma Corporation, and others.

What subsidiaries does NewAmsterdam Pharma Company have?

NewAmsterdam Pharma Company's subsidiaries include NewAmsterdam Pharma B.V., NewAmsterdam Pharma Corporation, NewAmsterdam Pharma Holding B.V..

Where is NewAmsterdam Pharma Company headquartered?

NewAmsterdam Pharma Company is headquartered in Netherlands and employs approximately 29 people. It has been publicly traded since 2022.

NewAmsterdam Pharma Company

NAMS

Market cap

$3.53B+40.3%

Revenue$22.6M-52.1%

Net income-$212.7M-13.5%

Free cash flow-$142.2M-1.0%

EPS (diluted)-$1.79+4.8%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$3.0MBeat by $1.3M EPS-$0.40Beat by $0.06

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$1.9M

EPS estimate-$0.48

Financials

Q1 2026

Income statement

See full

Revenue$3.0M+2.1%

Operating income-$58.4M+15.2%

Net income-$48.4M-22.6%

EPS (diluted)-$0.40-17.6%

Balance sheet

See full

Cash & equivalents$457.6M-38.9%

Total debt$23.0K-94.1%

Total equity$665.2M-14.4%

Total assets$732.6M-10.5%

Cash flow

See full

Operating cash flow-$30.6M+16.1%

CapEx$38.0K+138%

Free cash flow-$30.6M+16.0%

Valuation & ratios

Valuation

See full

Market cap$3.53B+40.3%

Enterprise value$3.08B+48.9%

P/S156.6×+115×

Profitability

See full

Operating margin-953.6%-3,536pp

Net margin-942.8%-3,477pp

FCF margin-630.1%-6,324pp

Returns & leverage

See full

Return on equity-29.5%-1.8pp

Debt / equity0×—

Current ratio9.8×-10.2×

Competitors

By market cap

Merck & Co.$322.95B+53.0%

Amgen$203.07B+25.3%

Regeneron Pharmaceuticals$69.9B+16.0%

NewAmsterdam Pharma Company$3.5B+34.4%

Atrium Therapeutics $197.9M-95.2%

RFL

Rafael Holdings, Inc.$118.6M+66.4%

iBio$72.0M+526%

MTV

MetaVia$7.5M-42.4%

By revenue growth

RFL

Rafael Holdings, Inc.+33.9%

Amgen+9.1%

Regeneron Pharmaceuticals+5.9%

Merck & Co.+2.9%

NewAmsterdam Pharma Company-52.1%

By net margin

Regeneron Pharmaceuticals29.65%-2.3pp

Amgen20.96%+3.6pp

Merck & Co.13.59%-13.7pp

NewAmsterdam Pharma Company-942.76%-545pp

RFL

Rafael Holdings, Inc.-2,117.24%+1,010pp

Profile

NewAmsterdam Pharma is a late-stage biopharmaceutical company focused on developing oral, low-dose therapies for cardiometabolic diseases, specifically targeting unmet needs in LDL-cholesterol lowering. Its lead product candidate, obicetrapib, is a selective CETP inhibitor designed to provide a safe and convenient alternative for patients who are statin-intolerant or unable to reach cholesterol goals with existing treatments. The company is also exploring the potential of CETP inhibition to mitigate risks in other indications, including Alzheimer's disease and diabetes.

Competitive position

A late-stage developer of a next-generation CETP inhibitor aiming to disrupt the lipid-lowering market currently dominated by statins and injectable PCSK9 inhibitors.

GeographiesUnited States, Europe, China, Japan

Customer segmentsPatients, Healthcare Providers

Business modelResearch and Development, Licensing and Royalties

SuppliersContract Manufacturing Organizations (CMOs), Clinical Research Organizations (CROs), Raw material suppliers for drug substance

CustomersPharmaceutical distributors, Hospitals and clinics, Retail pharmacies, Licensing partners

CountryNetherlands

Listed2022

Employees29.0

CEOMichael Davidson

SectorHealthcare

IndustryBiotechnology

Websitenewamsterdampharma.com

FilingsSEC EDGAR

Ask your AI about NewAmsterdam Pharma Company.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NewAmsterdam Pharma Company's market cap?: NewAmsterdam Pharma Company (NAMS) has a market capitalization of $3.5B and trades on NASDAQ.
What is NewAmsterdam Pharma Company's revenue and profitability?: NewAmsterdam Pharma Company generated $22.6M in trailing twelve-month revenue with a net loss of $212.7M, representing a net margin of -942.8%, with free cash flow of -$142.2M. These figures are based on the Q1 2026 filing.
Who are NewAmsterdam Pharma Company's competitors?: NewAmsterdam Pharma Company's key competitors include Amgen, Regeneron Pharmaceuticals, Merck & Co., and others. These companies compete in similar markets and product categories.
Who does NewAmsterdam Pharma Company partner with?: NewAmsterdam Pharma Company's notable partners include Menarini, Amgen, Mitsubishi Tanabe Pharma Corporation, and others.
What subsidiaries does NewAmsterdam Pharma Company have?: NewAmsterdam Pharma Company's subsidiaries include NewAmsterdam Pharma B.V., NewAmsterdam Pharma Corporation, NewAmsterdam Pharma Holding B.V..
Where is NewAmsterdam Pharma Company headquartered?: NewAmsterdam Pharma Company is headquartered in Netherlands and employs approximately 29 people. It has been publicly traded since 2022.